NextCell Pharma AB (FRA:65G)
Germany
· Delayed Price · Currency is EUR 0.0523
-0.0040 (-7.10%)
At close: Dec 5, 2025
NextCell Pharma AB Income Statement
Financials in millions SEK. Fiscal year is September - August.
Millions SEK. Fiscal year is Sep - Aug.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2016 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Aug '25 Aug 31, 2025 | Aug '24 Aug 31, 2024 | Aug '23 Aug 31, 2023 | Aug '22 Aug 31, 2022 | Aug '21 Aug 31, 2021 | 2016 - 2020 |
| Operating Revenue | 10.94 | 10.66 | 10.11 | 5.59 | 3.91 | Upgrade
|
| Other Revenue | 0.13 | 0.61 | 3.84 | 0.64 | 0.54 | Upgrade
|
| Revenue | 11.06 | 11.28 | 13.96 | 6.23 | 4.46 | Upgrade
|
| Revenue Growth (YoY) | -1.90% | -19.18% | 124.03% | 39.82% | 6.93% | Upgrade
|
| Cost of Revenue | 9.4 | 15.22 | 11 | 8.72 | 9.94 | Upgrade
|
| Gross Profit | 1.67 | -3.94 | 2.96 | -2.49 | -5.48 | Upgrade
|
| Selling, General & Admin | 34.9 | 38.22 | 43.47 | 31.85 | 18.84 | Upgrade
|
| Other Operating Expenses | 0.14 | 0.04 | 0.04 | 0.22 | 0.06 | Upgrade
|
| Operating Expenses | 37.55 | 39.23 | 43.96 | 32.53 | 19.34 | Upgrade
|
| Operating Income | -35.89 | -43.17 | -41 | -35.02 | -24.82 | Upgrade
|
| Interest Expense | -0 | -0 | -0 | -0.01 | -0.01 | Upgrade
|
| Interest & Investment Income | 0.75 | 1.21 | 1.19 | 0.48 | 0.27 | Upgrade
|
| Pretax Income | -35.14 | -41.96 | -39.81 | -34.55 | -24.56 | Upgrade
|
| Net Income | -35.14 | -41.96 | -39.81 | -34.55 | -24.56 | Upgrade
|
| Net Income to Common | -35.14 | -41.96 | -39.81 | -34.55 | -24.56 | Upgrade
|
| Shares Outstanding (Basic) | 76 | 41 | 34 | 34 | 30 | Upgrade
|
| Shares Outstanding (Diluted) | 76 | 41 | 34 | 34 | 30 | Upgrade
|
| Shares Change (YoY) | 87.22% | 18.72% | - | 13.05% | 53.09% | Upgrade
|
| EPS (Basic) | -0.46 | -1.03 | -1.16 | -1.01 | -0.81 | Upgrade
|
| EPS (Diluted) | -0.46 | -1.03 | -1.16 | -1.01 | -0.81 | Upgrade
|
| Free Cash Flow | -43.05 | -37.86 | -47.92 | -40.9 | -26.3 | Upgrade
|
| Free Cash Flow Per Share | -0.56 | -0.93 | -1.39 | -1.19 | -0.86 | Upgrade
|
| Gross Margin | 15.07% | -34.98% | 21.19% | -40.03% | -123.08% | Upgrade
|
| Operating Margin | -324.35% | -382.79% | -293.81% | -562.26% | -557.14% | Upgrade
|
| Profit Margin | -317.62% | -372.04% | -285.28% | -554.72% | -551.21% | Upgrade
|
| Free Cash Flow Margin | -389.04% | -335.70% | -343.41% | -656.63% | -590.41% | Upgrade
|
| EBITDA | -33.37 | -42.2 | -40.55 | -34.57 | -24.38 | Upgrade
|
| EBITDA Margin | - | - | -290.60% | - | - | Upgrade
|
| D&A For EBITDA | 2.52 | 0.97 | 0.45 | 0.46 | 0.44 | Upgrade
|
| EBIT | -35.89 | -43.17 | -41 | -35.02 | -24.82 | Upgrade
|
| EBIT Margin | - | - | -293.81% | - | - | Upgrade
|
| Revenue as Reported | 11.06 | 11.28 | 13.96 | 6.23 | 4.45 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.